PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Merrion Pharmaceuticals Garners Frost & Sullivan Osteoporosis Technology Innovation of the Year Award - Recognized for achievements in Technology Application, Innovation in the Osteoporosis markets
Merrion Pharmaceuticals Garners Frost & Sullivan Osteoporosis Technology Innovation of the Year Award

 

NewswireToday - /newswire/ - Mountain View, CA, United States, 2008/11/17 - Recognized for achievements in Technology Application, Innovation in the Osteoporosis markets.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Based on its recent analysis of the osteoporosis therapeutics market, Frost & Sullivan presents Merrion Pharmaceuticals (IEX:MERR) with the 2008 North American Frost & Sullivan Award for Osteoporosis Technology Innovation of the Year, in recognition of the company's successful application of its innovative gastrointestinal permeation enhancement technology (GIPET®) that creates an improved version of alendronate, MER-103 (Almerol™).

This innovative and novel technology has resulted in MER-103 (Almerol™), yielding such benefits as increased bioavailability, safety, and convenience, as compared to that of the currently marketed osteoporosis drug, Fosamax (alendronate).

Osteoporosis is the most prevalent bone disease in the United States, with an estimated 11.2 million Americans affected and an additional 46.4 million Americans having osteopenia or low bone mass. This group is at an increased risk of fractures, particularly of the hip, spine, and wrist, and the importance of new treatment options becomes more apparent. The active ingredient found in Fosamax, the U.S.'s top selling medication for osteoporosis in 2008, is alendronate. This popular bisphosphonate works by reducing the activity of osteoclasts, the cells that break down bone, and has proven effective at reducing the incidence of hip and spine fractures and improving bone mineral density.

“The currently available form of alendronate has poor bioavailability and is associated with unpleasant side effects, including esophageal and stomach irritation,” explains Frost & Sullivan Research Analyst Katheryn Symank. “Moreover, to increase bioavailability and to minimize gastrointestinal side effects, patients are faced with a complicated dosing regimen, which has resulted in poor patient compliance.”

The recommended dosage for the currently marketed drug, alendronate, is one pill taken with a full glass of water 30 minutes to one hour before any food intake. In addition, the patient is advised not to lie down for at least 30 minutes after taking their medication.

Merrion's GIPET® technology has enabled a novel formulation of alendronate MER-103 (Almerol™). With GIPET® technology, medications that are not well absorbed can be evolved to yield improved performance in characteristics such as bioavailability, drug efficacy, and safety. Not only does this allow for less of the active ingredient to be used to achieve the same therapeutic benefit, but it also can allow for more convenient dosing schedules. Moreover, the use of this technology does not require any chemical modification to the active ingredient.

“An oral version of alendronate, MER-103 (Almerol™) has an increase in bioavailability of 15-fold when taken at night, or 12-fold when taken after an overnight fast,” adds Symank. “This improvement allows for less alendronate to be used in the medication. For example, it estimated that 6mg of MER-103 (Almerol™) is equivalent to a 70 mg dose of oral alendronate's currently marketed formulation.”

In recognition of MER-103 (Almerol™)'s drug benefits – including improved bioavailability, a more attractive safety profile, and a simplified dosing regimen compared to that of the currently marketed formulation – that are important in improving drug development in the osteoporosis area, Frost & Sullivan is proud to present the 2008 Osteoporosis Technology Innovation of the Year Award to Merrion Pharmaceuticals.

Each year, Frost & Sullivan presents this award to the company that has demonstrated technological innovation within its industry. The award recognizes the ability of the company to successfully develop and introduce new/disruptive technology, formulate a well-designed product family, and make significant technology contributions to the industry.

Frost & Sullivan's Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About Merrion Pharmaceutical

Merrion Pharmaceuticals (merrionpharma.com) is a publicly listed specialty pharmaceutical company engaged in the development of oral forms (tablets/capsules) of drugs that have poor absorption and are generally given by injection. Merrion was established in 2004 to commercialise various technologies acquired from Elan Corporation, plc. Merrion's patented drug delivery technologies increase bioavailability, by improving absorption in the gastrointestinal tract, of drugs that are otherwise poorly absorbed. This can provide substantial benefit in patient convenience and safety, and might also provide enhanced drug efficacy. Merrion utilises its technology to develop new oral drugs in two ways; it develops its own proprietary drugs using GIPET® and partners with other pharmaceutical companies in developing oral GIPET® formulations of their products.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership™ empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents.

Wally Young, Young Communications
P: +353 (0)1 668-0530
E: youngcom[.]eircom.net.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Merrion Pharmaceuticals Garners Frost & Sullivan Osteoporosis Technology Innovation of the Year Award

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Frost & Sullivan |
Publisher Contact: Jake Wengroff 
210.247.3806 jake.wengroff[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application
Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  Triggr & Bloom





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)